The proteasome: a novel target for cancer chemotherapy
- PMID: 11960320
- DOI: 10.1038/sj.leu.2402417
The proteasome: a novel target for cancer chemotherapy
Abstract
The ubiquitin-proteasome system is an important regulator of cell growth and apoptosis. The potential of specific proteasome inhibitors to act as novel anti-cancer agents is currently under intensive investigation. Several proteasome inhibitors exert anti-tumour activity in vivo and potently induce apoptosis in tumour cells in vitro, including those resistant to conventional chemotherapeutic agents. By inhibiting NF-kappaB transcriptional activity, proteasome inhibitors may also prevent angiogenesis and metastasis in vivo and further increase the sensitivity of cancer cells to apoptosis. Proteasome inhibitors also exhibit some level of selective cytotoxicity to cancer cells by preferentially inducing apoptosis in proliferating or transformed cells or by overcoming deficiencies in growth-inhibitory or pro-apoptotic molecules. High expression of oncogene products like c-Myc also makes cancer cells more susceptible to proteasome inhibitor-induced apoptosis. The induction of apoptosis by proteasome inhibitors varies between cell types but often occurs following an initial accumulation of short-lived proteins such as p53, p27, pro-apoptotic Bcl-2 family members or activation of the stress kinase JNK. These initial events often result in a perturbation of mitochondria with concomitant release of cytochrome c and activation of the Apaf-1 containing apoptosome complex. This results in activation of the apical caspase-9 followed by activation of effector caspases-3 and -7, which are responsible for the biochemical and morphological changes associated with apoptosis.
Similar articles
-
Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells.Oncogene. 2003 May 1;22(17):2643-54. doi: 10.1038/sj.onc.1206326. Oncogene. 2003. PMID: 12730678
-
p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells.Clin Cancer Res. 2000 Mar;6(3):916-23. Clin Cancer Res. 2000. PMID: 10741716
-
The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells.Leukemia. 2003 Oct;17(10):2036-45. doi: 10.1038/sj.leu.2403109. Leukemia. 2003. PMID: 14513055
-
Regulation of apoptosis proteins in cancer cells by ubiquitin.Oncogene. 2004 Mar 15;23(11):2009-15. doi: 10.1038/sj.onc.1207373. Oncogene. 2004. PMID: 15021888 Review.
-
Targeting proteasome inhibition in hematologic malignancies.Rev Clin Exp Hematol. 2003 Jun;7(2):191-204. Rev Clin Exp Hematol. 2003. PMID: 14763162 Review.
Cited by
-
Caspase control: protagonists of cancer cell apoptosis.Exp Oncol. 2012 Oct;34(3):165-75. Exp Oncol. 2012. PMID: 23070001 Free PMC article. Review.
-
Proteolytic systems and AMP-activated protein kinase are critical targets of acute myeloid leukemia therapeutic approaches.Oncotarget. 2015 Oct 13;6(31):31428-40. doi: 10.18632/oncotarget.2947. Oncotarget. 2015. PMID: 25537507 Free PMC article.
-
Selective cytotoxicity of amidinopiperidine based compounds towards Burkitt's lymphoma cells involves proteasome inhibition.PLoS One. 2012;7(7):e41961. doi: 10.1371/journal.pone.0041961. Epub 2012 Jul 30. PLoS One. 2012. PMID: 22860040 Free PMC article.
-
APEH Inhibition Affects Osteosarcoma Cell Viability via Downregulation of the Proteasome.Int J Mol Sci. 2016 Sep 23;17(10):1614. doi: 10.3390/ijms17101614. Int J Mol Sci. 2016. PMID: 27669226 Free PMC article.
-
Regulation of Proteasomal Degradation by Modulating Proteasomal Initiation Regions.ACS Chem Biol. 2015 Nov 20;10(11):2537-43. doi: 10.1021/acschembio.5b00554. Epub 2015 Aug 21. ACS Chem Biol. 2015. PMID: 26278914 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous